{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T13:17:03Z","timestamp":1788268623638,"version":"build-2803163510"},"reference-count":40,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":1127,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1124\/jpet.121.000786","type":"journal-article","created":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T15:20:16Z","timestamp":1631892016000},"page":"280-289","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Selective Acetyl-CoA Carboxylase 1 Inhibitor Improves Hepatic Steatosis and Hepatic Fibrosis in a Preclinical Nonalcoholic Steatohepatitis Model"],"prefix":"10.1016","volume":"379","author":[{"given":"Yumiko Okano","family":"Tamura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Sugama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masako","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironobu","family":"Yasuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunobu","family":"Aoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek M.","family":"Erion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Yashiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.121.000786_bib1","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1126\/science.1056843","article-title":"Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2","volume":"291","author":"Abu-Elheiga","year":"2001","journal-title":"Science"},{"key":"10.1124\/jpet.121.000786_bib2","doi-asserted-by":"crossref","first-page":"10207","DOI":"10.1073\/pnas.1733877100","article-title":"Acetyl-CoA carboxylase 2 mutant mice are protected against obesity and diabetes induced by high-fat\/high-carbohydrate diets","volume":"100","author":"Abu-Elheiga","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.121.000786_bib3","doi-asserted-by":"crossref","first-page":"12011","DOI":"10.1073\/pnas.0505714102","article-title":"Mutant mice lacking acetyl-CoA carboxylase 1 are embryonically lethal","volume":"102","author":"Abu-Elheiga","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.121.000786_bib4","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrgastro.2013.41","article-title":"Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis","volume":"10","author":"Anstee","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1124\/jpet.121.000786_bib5","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jhep.2020.04.037","article-title":"Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation","volume":"73","author":"Bates","year":"2020","journal-title":"J Hepatol"},{"key":"10.1124\/jpet.121.000786_bib6","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/cpdd.782","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of a liver-targeting acetyl-CoA carboxylase inhibitor (PF\u201005221304): a three-part randomized phase 1 study","volume":"9","author":"Bergman","year":"2020","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1124\/jpet.121.000786_bib7","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1042\/bst0251232","article-title":"Isoforms of acetyl-CoA carboxylase: structures, regulatory properties and metabolic functions","volume":"25","author":"Brownsey","year":"1997","journal-title":"Biochem Soc Trans"},{"key":"10.1124\/jpet.121.000786_bib8","doi-asserted-by":"crossref","first-page":"774","DOI":"10.3390\/ijms17050774","article-title":"The natural course of non-alcoholic fatty liver disease","volume":"17","author":"Calzadilla Bertot","year":"2016","journal-title":"Int J Mol Sci"},{"key":"10.1124\/jpet.121.000786_bib9","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1080\/13543784.2019.1657825","article-title":"Acetyl-CoA carboxylase (ACC) as a therapeutic target for metabolic syndrome and recent developments in ACC1\/2 inhibitors","volume":"28","author":"Chen","year":"2019","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1124\/jpet.121.000786_bib10","doi-asserted-by":"crossref","first-page":"16480","DOI":"10.1073\/pnas.0706794104","article-title":"Continuous fat oxidation in acetyl-CoA carboxylase 2 knockout mice increases total energy expenditure, reduces fat mass, and improves insulin sensitivity","volume":"104","author":"Choi","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.121.000786_bib11","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1126\/science.1204265","article-title":"Human fatty liver disease: old questions and new insights","volume":"332","author":"Cohen","year":"2011","journal-title":"Science"},{"key":"10.1124\/jpet.121.000786_bib12","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial","volume":"165","author":"Cusi","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1124\/jpet.121.000786_bib13","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1172\/JCI23621","article-title":"Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease","volume":"115","author":"Donnelly","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1124\/jpet.121.000786_bib14","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jcmgh.2019.04.007","article-title":"Metabolic targets in nonalcoholic fatty liver disease","volume":"8","author":"Esler","year":"2019","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1124\/jpet.121.000786_bib15","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1053\/j.gastro.2007.11.038","article-title":"Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease","volume":"134","author":"Fabbrini","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1124\/jpet.121.000786_bib16","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat Med"},{"key":"10.1124\/jpet.121.000786_bib17","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1007\/s10620-014-3380-3","article-title":"Total body weight loss of \u2265 10 % is associated with improved hepatic fibrosis in patients with nonalcoholic steatohepatitis","volume":"60","author":"Glass","year":"2015","journal-title":"Dig Dis Sci"},{"key":"10.1124\/jpet.121.000786_bib18","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1055\/s-0031-1283138","article-title":"Stimulation of fat oxidation, but no sustained reduction of hepatic lipids by prolonged pharmacological inhibition of acetyl CoA carboxylase","volume":"43","author":"Glien","year":"2011","journal-title":"Horm Metab Res"},{"key":"10.1124\/jpet.121.000786_bib19","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1002\/hep.30097","article-title":"Acetyl-CoA carboxylase inhibition reverses NAFLD and hepatic insulin resistance but promotes hypertriglyceridemia in rodents","volume":"68","author":"Goedeke","year":"2018","journal-title":"Hepatology"},{"key":"10.1124\/jpet.121.000786_bib20","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1128\/MCB.01122-06","article-title":"Hepatic de novo lipogenesis is present in liver-specific ACC1-deficient mice","volume":"27","author":"Harada","year":"2007","journal-title":"Mol Cell Biol"},{"key":"10.1124\/jpet.121.000786_bib21","doi-asserted-by":"crossref","first-page":"E1796","DOI":"10.1073\/pnas.1520686113","article-title":"Acetyl-CoA carboxylase inhibition by ND-630 reduces hepatic steatosis, improves insulin sensitivity, and modulates dyslipidemia in rats","volume":"113","author":"Harriman","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.121.000786_bib22","doi-asserted-by":"crossref","first-page":"37099","DOI":"10.1074\/jbc.M304481200","article-title":"Isozyme-nonselective N-substituted bipiperidylcarboxamide acetyl-CoA carboxylase inhibitors reduce tissue malonyl-CoA concentrations, inhibit fatty acid synthesis, and increase fatty acid oxidation in cultured cells and in experimental animals","volume":"278","author":"Harwood","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.121.000786_bib23","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1016\/j.ajpath.2011.07.014","article-title":"Melanocortin 4 receptor-deficient mice as a novel mouse model of nonalcoholic steatohepatitis","volume":"179","author":"Itoh","year":"2011","journal-title":"Am J Pathol"},{"key":"10.1124\/jpet.121.000786_bib24","doi-asserted-by":"crossref","first-page":"4769","DOI":"10.1016\/j.bmcl.2012.05.062","article-title":"Symmetrical approach of spiro-pyrazolidinediones as acetyl-CoA carboxylase inhibitors","volume":"22","author":"Kamata","year":"2012","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1124\/jpet.121.000786_bib25","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.cmet.2017.07.009","article-title":"Acetyl CoA carboxylase inhibition reduces hepatic steatosis but elevates plasma triglycerides in mice and humans: a bedside to bench investigation","volume":"26","author":"Kim","year":"2017","journal-title":"Cell Metab"},{"key":"10.1124\/jpet.121.000786_bib26","first-page":"351","article-title":"Re-evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease","volume":"20","author":"Kohjima","year":"2007","journal-title":"Int J Mol Med"},{"key":"10.1124\/jpet.121.000786_bib27","doi-asserted-by":"crossref","first-page":"e0121528","DOI":"10.1371\/journal.pone.0121528","article-title":"Eicosapentaenoic acid ameliorates non-alcoholic steatohepatitis in a novel mouse model using melanocortin 4 receptor-deficient mice","volume":"10","author":"Konuma","year":"2015","journal-title":"PLoS One"},{"key":"10.1124\/jpet.121.000786_bib28","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1053\/j.gastro.2013.11.049","article-title":"Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease","volume":"146","author":"Lambert","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1124\/jpet.121.000786_bib29","doi-asserted-by":"crossref","first-page":"8552","DOI":"10.1073\/pnas.0603115103","article-title":"Liver-specific deletion of acetyl-CoA carboxylase 1 reduces hepatic triglyceride accumulation without affecting glucose homeostasis","volume":"103","author":"Mao","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.121.000786_bib30","doi-asserted-by":"crossref","first-page":"e0228212","DOI":"10.1371\/journal.pone.0228212","article-title":"Acetyl-CoA carboxylase 1 and 2 inhibition ameliorates steatosis and hepatic fibrosis in a MC4R knockout murine model of nonalcoholic steatohepatitis","volume":"15","author":"Matsumoto","year":"2020","journal-title":"PLoS One"},{"key":"10.1124\/jpet.121.000786_bib31","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1021\/acs.jmedchem.7b01547","article-title":"Discovery of novel selective acetyl-CoA carboxylase (ACC) 1 inhibitors","volume":"61","author":"Mizojiri","year":"2018","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.121.000786_bib32","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/j.cgh.2008.08.012","article-title":"Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis","volume":"6","author":"Mummadi","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1124\/jpet.121.000786_bib33","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.121.000786_bib34","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1172\/JCI27300","article-title":"Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2","volume":"116","author":"Savage","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1124\/jpet.121.000786_bib35","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1038\/s41598-018-19658-7","article-title":"Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH","volume":"8","author":"Shiba","year":"2018","journal-title":"Sci Rep"},{"key":"10.1124\/jpet.121.000786_bib36","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1002\/hep.29607","article-title":"Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science","volume":"67","author":"Siddiqui","year":"2018","journal-title":"Hepatology"},{"key":"10.1124\/jpet.121.000786_bib37","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1365-2036.2011.04724.x","article-title":"Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults","volume":"34","author":"Vernon","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1124\/jpet.121.000786_bib38","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1053\/j.gastro.2010.09.038","article-title":"Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study","volume":"140","author":"Williams","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1124\/jpet.121.000786_bib39","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/hep.30251","article-title":"Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatology"},{"key":"10.1124\/jpet.121.000786_bib40","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1097\/00042737-200409000-00013","article-title":"Correlation of serum aminotransferases with HCV RNA levels and histological findings in patients with chronic hepatitis C: the role of serum aspartate transaminase in the evaluation of disease progression","volume":"16","author":"Zechini","year":"2004","journal-title":"Eur J Gastroenterol Hepatol"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524270920?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524270920?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.121.000786","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T14:02:58Z","timestamp":1739973778000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524270920"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S0022356524270920"],"URL":"https:\/\/doi.org\/10.1124\/jpet.121.000786","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Selective Acetyl-CoA Carboxylase 1 Inhibitor Improves Hepatic Steatosis and Hepatic Fibrosis in a Preclinical Nonalcoholic Steatohepatitis Model","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.121.000786","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s)","name":"copyright","label":"Copyright"}]}}